SCHEMBL25920586

SCHEMBL25920586

COc1cccc(NC(=O)Nc2cc(Cl)ncn2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
RAB9A P51151 8/20 0.60
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
TP53 P04637 1/20 0.59
TSHR P16473 1/20 0.59
ALDH1A1 P00352 1/20 0.59
EGFR P00533 2/20 0.58
FGFR1 P11362 1/20 0.58
MAPT P10636 6/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
ERBB3 P21860 1/20 0.56
TUBB4A P04350 1/20 0.56
TUBB P07437 1/20 0.56
TUBA3C P0DPH7 1/20 0.56
TUBA1B P68363 1/20 0.56
TUBA4A P68366 1/20 0.56
TUBB4B P68371 1/20 0.56
TUBB3 Q13509 1/20 0.56
TUBB2A Q13885 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270579 1.00 NPC1 (0.60) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL373717 0.86 EGFR (0.80) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL855961 0.84 EGFR (0.77) NPC1RAB9AMEN1KMT2AEGFR
SCHEMBL29556785 0.83 ALDH1A1 (0.71) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL4893387 0.81 TP53 (0.87) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL31040569 0.81 TP53 (0.87) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL29555884 0.80 MAPT (0.67) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL17084260 0.79 TP53 (0.84) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL374439 0.79 EGFR (0.72) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL25002342 0.78 MAPT (0.73) NPC1RAB9AMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
EP-4164622-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA Icahn School of Medicine at Mount Sinai (US) 2023-04-19 EP disclosed
WO-2021257544-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 NPC1 2197/4885RAB9A 1163/4885MEN1 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.